Real-time imaging of oxidative and nitrosative stress in the liver of live animals for drug-toxicity testing

Nature Biotechnology

Volumn 32, Issue 4, 2014, Pages 373-380

  Shuhendler, Adam J ^a   Pu, Kanyi ^a   Cui, Lina ^a   Uetrecht, Jack P ^b   Rao, Jianghong ^a  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMARKERS; ENERGY TRANSFER; NANOSENSORS;

CHEMILUMINESCENCERESONANCE-ENERGY TRANSFERS (CRET); DIRECT EVALUATIONS; FLUORESCENCE RESONANCE ENERGY TRANSFER; HISTOLOGICAL CHANGES; INDEPENDENT CHANNELS; NITROSATIVE STRESS; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES;

DRUG DOSAGE;

DOUBLE STRANDED DNA; GLUTATHIONE; ISONIAZID; PARACETAMOL; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; NANOPARTICLE; POLYMER;

ABSORPTION SPECTROSCOPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DAMAGE; CELL DEATH; CHEMILUMINESCENCE RESONANCE ENERGY TRANSFER; CHEMOLUMINESCENCE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DNA FRAGMENTATION; DOUBLE STRANDED DNA BREAK; ENERGY TRANSFER; FEMALE; FLUORESCENCE IMAGING; FLUORESCENCE RESONANCE ENERGY TRANSFER; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIGHT SCATTERING; LIVER; LIVER TOXICITY; MOUSE; NANOSENSOR; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN MODIFICATION; RESPIRATORY BURST; SENSITIVITY AND SPECIFICITY; TOXICITY TESTING; TRANSMISSION ELECTRON MICROSCOPY; ANIMAL; CHEMICAL MODEL; CHEMISTRY; DRUG EFFECTS; METABOLISM; NANOTECHNOLOGY; NUDE MOUSE; PROCEDURES; TOXIC HEPATITIS; TOXICITY; WHOLE BODY IMAGING;

ACETAMINOPHEN; ANIMALS; DRUG-INDUCED LIVER INJURY; FEMALE; FLUORESCENCE RESONANCE ENERGY TRANSFER; ISONIAZID; LIVER; MICE; MICE, NUDE; MODELS, CHEMICAL; NANOPARTICLES; NANOTECHNOLOGY; OPTICAL IMAGING; OXIDATIVE STRESS; POLYMERS; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES; TOXICITY TESTS; WHOLE BODY IMAGING;

EID: 84900870276     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.2838     Document Type: Article

References (55)

1. Nasr, A., Lauterio, T.J. & Davis, M.W. Unapproved drugs in the United States and the Food and Drug Administration. Adv. Ther. 28, 842-856 (2011).
2. Budnitz, D.S. et al. National surveillance of emergency department visits for outpatient adverse drug events. J. Am. Med. Assoc. 296, 1858-1866 (2006).
3. Sakatis, M.Z. et al. Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for 200 compounds. Chem. Res. Toxicol. 25, 2067-2082 (2012).
4. Srivastava, A. et al. Role of reactive metabolites in drug-induced hepatotoxicity. Handb. Exp. Pharmacol. 196, 165-194 (2010).
5. Dimasi, J.A. Risks in new drug development: approval success rates for investigational drugs. Clin. Pharmacol. Ther. 69, 297-307 (2001).
6. Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3, 711-715 (2004).
7. Tengowski, M.W. & Kotyk, J.J. Risk identification and management: MRI as a research tool in toxicology studies of new chemical entities. Prog. Drug Res. 62, 257-278 (2005).
8. Kramer, J.A., Sagartz, J.E. & Morris, D.L. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. Nat. Rev. Drug Discov. 6, 636-649 (2007).
9. Holt, M. & Ju, C. Drug-induced liver injury. Handb. Exp. Pharmacol. 196, 3-27 (2010).
10. Walsh, J.S. & Miwa, G.T. Bioactivation of drugs: risk and drug design. Annu. Rev. Pharmacol. Toxicol. 51, 145-167 (2011).
11. Antoine, D.J., Williams, D.P. & Park, B.K. Understanding the role of reactive metabolites in drug-induced hepatotoxicity: state of the science. Expert Opin. Drug Metab. Toxicol. 4, 1415-1427 (2008).
12. Tang, W. & Lu, A.Y. Metabolic bioactivation and drug-related adverse effects: current status and future directions from a pharmaceutical research perspective. Drug Metab. Rev. 42, 225-249 (2010).
13. Willmann, J.K., van Bruggen, N., Dinkelborg, L.M. & Gambhir, S.S. Molecular imaging in drug development. Nat. Rev. Drug Discov. 7, 591-607 (2008).
14. Pessayre, D., Mansouri, A., Berson, A. & Fromenty, B. Mitochondrial involvement in drug-induced liver injury. Handb. Exp. Pharmacol. 196, 311-365 (2010).
15. Russmann, S., Kullak-Ublick, G.A. & Grattagliano, I. Current concepts of mechanisms in drug-induced hepatotoxicity. Curr. Med. Chem. 16, 3041-3053 (2009).
16. Xiong, L., Shuhendler, A.J. & Rao, J. Self-luminescing BRET-FRET near-infrared dots for in vivo lymph-node mapping and tumour imaging. Nat. Commun. 3, 1193 (2012).
17. Pu, K., Shuhendler, A.J. & Rao, J. Semiconducting polymer nanoprobe for in vivo imaging of reactive oxygen and nitrogen species. Angew. Chem. Int. Edn. Engl. 52, 10325-10329 (2013).
18. Lee, D. et al. In vivo imaging of hydrogen peroxide with chemiluminescent nanoparticles. Nat. Mater. 6, 765-769 (2007).
19. Oushiki, D. et al. Development and application of a near-infrared fluorescence probe for oxidative stress based on differential reactivity of linked cyanine dyes. J. Am. Chem. Soc. 132, 2795-2801 (2010).
20. Hu, Y., Haynes, M.T., Wang, Y., Liu, F. & Huang, L. A highly efficient synthetic vector: nonhydrodynamic delivery of DNA to hepatocyte nuclei in vivo. ACS Nano 7, 5376-5384 (2013).
21. Szabo, C., Ischiropoulos, H. & Radi, R. Peroxynitrite: biochemistry, pathophysiology and development of therapeutics. Nat. Rev. Drug Discov. 6, 662-680 (2007).
22. Smith, A.M., Mancini, M.C. & Nie, S. Bioimaging: second window for in vivo imaging. Nat. Nanotechnol. 4, 710-711 (2009).
23. Shuhendler, A.J. et al. Hybrid quantum dot-fatty ester stealth nanoparticles: toward clinically relevant in vivo optical imaging of deep tissue. ACS Nano 5, 1958-1966 (2011).
24. Pu, K. et al. Semiconducting polymer nanoparticles as photoacoustic molecular imaging probes in living mice. Nat. Nanotechnol. doi:10.1038/nnano. 2013.302 (26 January 2014).
25. Herd, R.M., Dover, J.S. & Arndt, K.A. Basic laser principles. Dermatol. Clin. 15, 355-372 (1997).
26. Mourant, J.R., Fuselier, T., Boyer, J., Johnson, T.M. & Bigio, I.J. Predictions and measurements of scattering and absorption over broad wavelength ranges in tissue phantoms. Appl. Opt. 36, 949-957 (1997).
27. Jones, C.F. & Grainger, D.W. In vitro assessments of nanomaterial toxicity. Adv. Drug Deliv. Rev. 61, 438-456 (2009).
28. Maynard, A.D., Warheit, D.B. & Philbert, M.A. The new toxicology of sophisticated materials: nanotoxicology and beyond. Toxicol. Sci. 120 (suppl. 1), S109-S129 (2011).
29. Hinson, J.A., Roberts, D.W. & James, L.P. Mechanisms of acetaminophen-induced liver necrosis. Handb. Exp. Pharmacol. 196, 369-405 (2010).
30. Nakagawa, H. et al. Deletion of apoptosis signal-regulating kinase 1 attenuates acetaminophen-induced liver injury by inhibiting c-Jun N-terminal kinase activation. Gastroenterology 135, 1311-1321 (2008).
31. McGill, M.R. & Jaeschke, H. Metabolism and disposition of acetaminophen: recent advances in relation to hepatotoxicity and diagnosis. Pharm. Res. 30, 2174-2187 (2013).
32. Gujral, J.S., Knight, T.R., Farhood, A., Bajt, M.L. & Jaeschke, H. Mode of cell death after acetaminophen overdose in mice: apoptosis or oncotic necrosis? Toxicol. Sci. 67, 322-328 (2002).
33. Liu, W.F. et al. Real-time in vivo detection of biomaterial-induced reactive oxygen species. Biomaterials 32, 1796-1801 (2011).
34. James, L.P., McCullough, S.S., Lamps, L.W. & Hinson, J.A. Effect of N-acetylcysteine on acetaminophen toxicity in mice: relationship to reactive nitrogen and cytokine formation. Toxicol. Sci. 75, 458-467 (2003).
35. Jackson, T.E., Lilly, P.D., Recio, L., Schlosser, P.M. & Medinsky, M.A. Inhibition of cytochrome P450 2E1 decreases, but does not eliminate, genotoxicity mediated by 1,3-butadiene. Toxicol. Sci. 55, 266-273 (2000).
36. Saito, C., Zwingmann, C. & Jaeschke, H. Novel mechanisms of protection against acetaminophen hepatotoxicity in mice by glutathione and N-acetylcysteine. Hepatology 51, 246-254 (2010).
37. Saukkonen, J.J., Powell, K. & Jereb, J.A. Monitoring for tuberculosis drug hepatotoxicity: moving from opinion to evidence. Am. J. Respir. Crit. Care Med. 185, 598-599 (2012).
38. Metushi, I.G., Nakagawa, T. & Uetrecht, J. Direct oxidation and covalent binding of isoniazid to rodent liver and human hepatic microsomes: humans are more like mice than rats. Chem. Res. Toxicol. 25, 2567-2576 (2012).
39. Metushi, I.G., Cai, P., Zhu, X., Nakagawa, T. & Uetrecht, J.P. A fresh look at the mechanism of isoniazid-induced hepatotoxicity. Clin. Pharmacol. Ther. 89, 911-914 (2011).
40. Peet, J. et al. Efficiency enhancement in low-bandgap polymer solar cells by processing with alkane dithiols. Nat. Mater. 6, 497-500 (2007).
41. Sokolov, A.N., Tee, B.C., Bettinger, C.J., Tok, J.B. & Bao, Z. Chemical and engineering approaches to enable organic field-effect transistors for electronic skin applications. Acc. Chem. Res. 45, 361-371 (2012).
42. Wu, C. & Chiu, D.T. Highly fluorescent semiconducting polymer dots for biology and medicine. Angew. Chem. Int. Edn. Engl. 52, 3086-3109 (2013).
43. Guimard, N.K., Sessler, J.L. & Schmidt, C.E. Towards a biocompatible, biodegradable copolymer incorporating electroactive oligothiophene units. Macromolecules 42, 502-511 (2009).
44. Zhang, N., Francis, K.P., Prakash, A. & Ansaldi, D. Enhanced detection of myeloperoxidase activity in deep tissues through luminescent excitation of near-infrared nanoparticles. Nat. Med. 19, 500-505 (2013).
45. Park, B.K., Kitteringham, N.R., Maggs, J.L., Pirmohamed, M. & Williams, D.P. The role of metabolic activation in drug-induced hepatotoxicity. Annu. Rev. Pharmacol. Toxicol. 45, 177-202 (2005).
46. Cover, C. et al. Peroxynitrite-induced mitochondrial and endonuclease-mediated nuclear DNA damage in acetaminophen hepatotoxicity. J. Pharmacol. Exp. Ther. 315, 879-887 (2005).
47. McGill, M.R. et al. Plasma and liver acetaminophen-protein adduct levels in mice after acetaminophen treatment: dose-response, mechanisms, and clinical implications. Toxicol. Appl. Pharmacol. 269, 240-249 (2013).
48. Ghafourifar, P. & Cadenas, E. Mitochondrial nitric oxide synthase. Trends Pharmacol. Sci. 26, 190-195 (2005).
49. Pacher, P., Beckman, J.S. & Liaudet, L. Nitric oxide and peroxynitrite in health and disease. Physiol. Rev. 87, 315-424 (2007).
50. Chowdhury, A. et al. Mitochondrial oxidative stress and permeability transition in isoniazid and rifampicin induced liver injury in mice. J. Hepatol. 45, 117-126 (2006).
51. Li, F. et al. Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co-therapy. Nat. Med. 19, 418-420 (2013).
52. Lauterburg, B.H., Smith, C.V., Todd, E.L. & Mitchell, J.R. Pharmacokinetics of the toxic hydrazino metabolites formed from isoniazid in humans. J. Pharmacol. Exp. Ther. 235, 566-570 (1985).
53. Nathan, C. & Cunningham-Bussel, A. Beyond oxidative stress: an immunologists guide to reactive oxygen species. Nat. Rev. Immunol. 13, 349-361 (2013).
54. Li, J.O.W., Li, W., Jiang, Z.G. & Ghanbari, H.A. Oxidative stress and neurodegenerative disorders. Int. J. Mol. Sci. 14, 24438-24475 (2013).
55. Costa, A., Scholer-Dahirel, A. & Mechta-Grigoriou, F. The role of reactive oxygen species and metabolism on cancer cells and their microenvironment. Semin. Cancer Biol. doi:10.1016/j.semcancer.2013.12.007 (7 January 2014).